Scientists at Scripps Research have identified a specific chemical modification on the STING protein that appears to lock brain immune cells into a state of chronic inflammation in Alzheimer’s disease. The modification, called S-nitrosylation at cysteine 148, was found in postmortem human brain tissue, in lab-grown human microglia, and in a widely used Alzheimer’s mouse model. When the research team blocked that modification, microglial activation dropped, cytokine release fell, and synapses were preserved, offering a potential new drug target that could slow neuron loss without shutting down the entire immune system.
What is verified so far
The core finding comes from a peer-reviewed study in Cell Chemical Biology, led by senior author Stuart Lipton at Scripps Research. The team reports that STING, a protein best known for detecting viral DNA and triggering innate immune responses, is chemically altered in Alzheimer’s brains through S-nitrosylation. That alteration occurs at a single amino acid position, cysteine 148, and the resulting molecule is designated SNO-STING. The modification was detected in three independent settings: postmortem human Alzheimer’s brain tissue, human induced pluripotent stem cell-derived microglia exposed to amyloid-beta and alpha-synuclein aggregates, and 5xFAD transgenic mice, a standard genetic model of Alzheimer’s pathology.
The mechanism matters because it offers a concrete explanation for how inflammation persists long after the initiating triggers should have faded. Under normal conditions, the enzyme cGAS senses damaged or misplaced DNA and produces a cyclic dinucleotide messenger that switches STING on. STING then activates downstream inflammatory signals and, after a burst of activity, turns back off. In Alzheimer’s tissue, S-nitrosylation at cysteine 148 appears to promote abnormal STING oligomerization, essentially jamming the protein in its “on” position. That keeps microglia, the brain’s resident immune cells, firing inflammatory signals continuously, damaging nearby neurons and synapses in the process.
This new redox mechanism builds on earlier independent work. A separate study in Nature Aging showed that cGAS-STING signaling is activated in human Alzheimer’s brains and in aged mice, and that genetically deleting cGAS in 5xFAD animals protected them from hallmark pathology. That prior evidence established the pathway as relevant to Alzheimer’s but left open the question of why it stays active. The Scripps finding fills that gap: S-nitrosylation at cysteine 148 provides a plausible molecular reason the switch remains flipped in chronically inflamed brain tissue.
According to institutional statements, Lipton has emphasized the translational angle, noting that blocking the modification reduced inflammation and protected neurons in the mouse model. The framing suggests a drug target that could be hit selectively, dampening chronic neuroinflammation without broadly suppressing the immune defenses the brain still needs against infections and other insults.
The study also benefits from converging lines of evidence. The authors used biochemical assays to confirm S-nitrosylation on STING, imaging to visualize microglial activation, and electrophysiological and histological measures to assess synaptic integrity. In the 5xFAD mice, interventions that prevented SNO-STING formation or disrupted its oligomerization led to measurable improvements in synaptic markers and reductions in inflammatory cytokines. These experiments strengthen the argument that the modification is not merely a byproduct of disease but an active driver of pathology.
What remains uncertain
The gap between a mouse experiment and a human therapy is wide, and several pieces of evidence are still missing. No published data yet link SNO-STING levels in living patients to cognitive decline measured by imaging or standardized testing. The postmortem tissue confirms the modification exists in human Alzheimer’s brains, but it cannot tell researchers whether higher SNO-STING levels predict faster disease progression or whether reducing those levels would change clinical outcomes.
On the drug development side, no candidate compound targeting cysteine 148 has entered the formal toxicology studies required before human trials. Questions about whether such a molecule can cross the blood-brain barrier in sufficient concentrations, how it behaves in larger mammals, and whether it spares the beneficial antiviral functions of the cGAS-STING pathway all remain open. The Cell Chemical Biology paper and the associated preprint version describe the biology in detail but do not report pharmacokinetic data or dose–response curves for any therapeutic candidate.
Cell-type specificity is another unresolved question. The strongest evidence centers on microglia, where STING activation is best characterized and where SNO-STING seems clearly linked to inflammatory gene expression. Whether neurons themselves carry SNO-STING and suffer direct damage from it, or whether they are harmed primarily by the inflammatory environment microglia create, has not been fully separated in human tissue. Some review literature also suggests that STING signaling may involve cells of the brain microvasculature, potentially influencing blood–brain barrier integrity, a layer of complexity the current study does not address.
Timing is uncertain as well. It is not yet clear when SNO-STING first appears during the course of Alzheimer’s pathology, whether it tracks more closely with amyloid deposition, tau tangle formation, or downstream neurodegeneration, and whether its levels change as symptoms progress from mild cognitive impairment to more severe dementia. Longitudinal studies in animal models, and eventually biomarker work in humans, would be needed to place SNO-STING on the disease timeline.
How to read the evidence
The most solid claims in this story rest on primary experimental data: the identification of the cysteine 148 modification, its presence in human tissue and multiple model systems, and the functional rescue seen in 5xFAD mice when the modification is blocked. These findings were published in a peer-reviewed journal and align with earlier evidence that disabling cGAS in the same mouse model reduces pathology. Together, they make a compelling mechanistic case that aberrant STING activation contributes to neurodegeneration in Alzheimer’s disease.
At the same time, the work is still preclinical. The findings justify calling SNO-STING a promising target for drug discovery, but they do not yet justify claims about slowing or reversing dementia in people. Any such statements remain speculative until compounds that modulate SNO-STING are tested in rigorous clinical trials with cognitive and functional endpoints.
Readers should also distinguish between pathway-level and disease-level causality. The data support a model in which SNO-STING helps sustain chronic neuroinflammation and synaptic damage, but Alzheimer’s is a multifactorial disorder involving amyloid, tau, vascular changes, and metabolic and genetic risk factors. Even if SNO-STING proves to be an important node, modulating it is unlikely to be a complete solution on its own. Instead, it may become one component of combination approaches that address several aspects of the disease simultaneously.
For now, the evidence is strong enough to reshape how scientists think about innate immunity in the aging brain. Rather than viewing STING activation as a simple on–off response to DNA damage, the new work highlights a redox-sensitive checkpoint that can lock the system into a harmful steady state. Whether drug developers can safely reset that checkpoint in humans is the next question-and one that will require years of additional research before definitive answers emerge.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
